163 related articles for article (PubMed ID: 34818480)
21. Identification of Novel Mutations and Expressions of
Islam F; Pillai S; Gopalan V; Lam AK
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114456
[TBL] [Abstract][Full Text] [Related]
22. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
[TBL] [Abstract][Full Text] [Related]
23. Developmental vascular malformations in EPAS1 gain-of-function syndrome.
Rosenblum JS; Wang H; Dmitriev PM; Cappadona AJ; Mastorakos P; Xu C; Jha A; Edwards N; Donahue DR; Munasinghe J; Nazari MA; Knutsen RH; Rosenblum BR; Smirniotopoulos JG; Pappo A; Spetzler RF; Vortmeyer A; Gilbert MR; McGavern DB; Chew E; Kozel BA; Heiss JD; Zhuang Z; Pacak K
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33497361
[TBL] [Abstract][Full Text] [Related]
24. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas.
Yang C; Sun MG; Matro J; Huynh TT; Rahimpour S; Prchal JT; Lechan R; Lonser R; Pacak K; Zhuang Z
Blood; 2013 Mar; 121(13):2563-6. PubMed ID: 23361906
[TBL] [Abstract][Full Text] [Related]
25. Ocular manifestations of hypoxia-inducible factor-2α paraganglioma-somatostatinoma-polycythemia syndrome.
Pacak K; Chew EY; Pappo AS; Yang C; Lorenzo FR; Wilson MW; Aronow MB; Young JA; Popovic V; Zhuang Z
Ophthalmology; 2014 Nov; 121(11):2291-3. PubMed ID: 25109928
[No Abstract] [Full Text] [Related]
26. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
[TBL] [Abstract][Full Text] [Related]
27. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
Toledo R; Jimenez C
F1000Res; 2018; 7():. PubMed ID: 30109021
[TBL] [Abstract][Full Text] [Related]
29. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma.
Lorenzo FR; Yang C; Ng Tang Fui M; Vankayalapati H; Zhuang Z; Huynh T; Grossmann M; Pacak K; Prchal JT
J Mol Med (Berl); 2013 Apr; 91(4):507-12. PubMed ID: 23090011
[TBL] [Abstract][Full Text] [Related]
30. HIF2 and endocrine neoplasia: an evolving story.
Maher ER
Endocr Relat Cancer; 2013 Jun; 20(3):C5-7. PubMed ID: 23653463
[TBL] [Abstract][Full Text] [Related]
31. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
Tella SH; Taïeb D; Pacak K
Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model.
Metelo AM; Noonan HR; Li X; Jin Y; Baker R; Kamentsky L; Zhang Y; van Rooijen E; Shin J; Carpenter AE; Yeh JR; Peterson RT; Iliopoulos O
J Clin Invest; 2015 May; 125(5):1987-97. PubMed ID: 25866969
[TBL] [Abstract][Full Text] [Related]
33. Somatic Mosaicism of EPAS1 Mutations in Pacak-Zhuang Syndrome.
Wang H; Zhuang Z; Rosenblum JS; Pacak K
Endocr Pract; 2022 Jul; 28(7):734-735. PubMed ID: 35489703
[No Abstract] [Full Text] [Related]
34. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
[TBL] [Abstract][Full Text] [Related]
35. Functional significance of germline EPAS1 variants.
Dwight T; Kim E; Bastard K; Benn DE; Eisenhofer G; Richter S; Mannelli M; Rapizzi E; Prejbisz A; Pęczkowska M; Pacak K; Clifton-Bligh R
Endocr Relat Cancer; 2021 Feb; 28(2):97-109. PubMed ID: 33300499
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive
Karaghiannis V; Maric D; Garrec C; Maaziz N; Buffet A; Schmitt L; Antunes V; Airaud F; Aral B; Le Roy A; Corbineau S; Mansour-Hendili L; Lesieur V; Rimbert A; Laporte F; Delamare M; Rab M; Bézieau S; Cassinat B; Galacteros F; Gimenez-Roqueplo AP; Burnichon N; Cario H; Van Wijk R; Bento C; Girodon F; Hoogewijs D; Gardie B
Haematologica; 2023 Jun; 108(6):1652-1666. PubMed ID: 36700397
[TBL] [Abstract][Full Text] [Related]
37. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
[TBL] [Abstract][Full Text] [Related]
39. A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An
Wang H; Cui J; Yang C; Rosenblum JS; Zhang Q; Song Q; Pang Y; Fang F; Sun M; Dmitriev P; Gilbert MR; Eisenhofer G; Pacak K; Zhuang Z
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31091718
[TBL] [Abstract][Full Text] [Related]
40. EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease.
Vaidya A; Flores SK; Cheng ZM; Nicolas M; Deng Y; Opotowsky AR; Lourenço DM; Barletta JA; Rana HQ; Pereira MA; Toledo RA; Dahia PLM
N Engl J Med; 2018 Mar; 378(13):1259-1261. PubMed ID: 29601261
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
